Danaher Unit Receives FDA Clearance for Opioid-Induced Respiratory Depression Detection Feature

MT Newswires Live06-22

Danaher's (DHR) Masimo said Monday it received US Food and Drug Administration clearance for an opioid-induced respiratory depression detection capability integrated into the Radius VSM wearable continuous patient monitor.

The company said the feature, enabled by Masimo's next-generation smartSET pulse oximetry sensor platform, uses pattern-recognition technology to analyze continuous physiological data and help clinicians identify early signs of respiratory compromise in hospital patients receiving opioid therapy.

The feature includes visual alarms that alert clinicians to rising OIRD risk and can relay alarms to remote and centralized monitoring stations, it added.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment